Comprehensive Study Notes on Lipids and Dyslipidemias: Clinical Guidelines and Pathophysiology

Lipids of Clinical Importance

Lipids are essential biological molecules with diverse functions in the human body. Triglycerides are characterized by being esterified to glycerol and serve as the principal constituent of lipoproteins; they are primarily used for energy storage within adipose tissue. Phospholipids consist of lipids esterified to an alcohol and another group, serving as structural constituents of cellular membranes, lipoproteins, and surfactants. Cholesterol acts as a vital lipid precursor or derivative, serving as a constituent of cell membranes and a precursor for the synthesis of hormones, vitamins, and bile acids.

Metabolism and Metabolic Pathways of Cholesterol

The absorption of dietary lipids involves a digestive or intraluminal phase where fats undergo physical and chemical modification. Once absorbed, cholesterol participates in several metabolic pathways, including the synthesis of compounds necessary for cellular proliferation, electrolytic transport, and the management of oxidative stress. In the blood, cholesterol exists in two forms: approximately $30\%$ is in free form, while the remaining $70\%$ consists of esterified cholesterol.

The esterification process is regulated by enzymes such as Lecithin-cholesterol acyltransferase (LCAT) and Acyl-CoA:cholesterol acyltransferase (ACAT). Hepatic regulation is significant, as $70-80\%$ of cholesterol is recaptured by the liver. Intracellularly, the concentration of cholesterol is controlled by the HMG-CoA reductase enzyme, which is the rate-limiting step in cholesterol synthesis. This enzyme is targeted by statin drugs. Additionally, SREBP transcription factors control gene expression related to cholesterol levels, while ACAT facilitates the storage of cholesterol as esters.

Bile Acids and Enterohepatic Circulation

Bile acids are synthesized in the liver from cholesterol, a process initiated by the enzyme $7\alpha-cholesterol\,hydroxylase$. Primary bile acids produced in the liver include cholic acid and chenodeoxycholic acid. These are often conjugated with glycine or taurine to form glycocholic acid, glycochenodeoxycholic acid, taurocholic acid, and taurochenodeoxycholic acid.

Once secreted into the intestine, primary bile acids are transformed by intestinal bacteria into secondary bile acids, specifically deoxycholic acid and lithocholic acid. The enterohepatic circulation allows for the reabsorption of most bile acids back to the liver, while a small portion is excreted in the feces. This cycle is crucial for the emulsification and absorption of dietary fats.

Steroid Hormones and Steroidogenesis

Cholesterol serves as the universal precursor for all steroid hormones. This production occurs specifically in the adrenal cortex, testicles, and ovaries. The process of steroidogenesis is tightly controlled by enzymes of the cytochrome P-450 monooxygenase (Cyt.P-450) system.

Lipoprotein Structure and Apolipoproteins

Lipoproteins are complex particles designed to transport hydrophobic lipids through the aqueous environment of the plasma. They possess a hydrophilic external surface and a hydrophobic interior. The outer shell contains free cholesterol, phospholipids, and apolipoproteins, while the core contains cholesterol esters and triacylglycerols (triglycerides).

Apolipoproteins (Apos) serve various functions in lipoprotein metabolism. Apo AI, synthesized in the intestine and liver, has a molecular weight of $29\,kDa$ and acts as a cofactor for LCAT, primarily found in HDL. Apo B-48 ($240.8\,kDa$), synthesized in the intestine, is essential for Chylomicron lipidation. Apo B-100 ($512.7\,kDa$), synthesized in the liver, is crucial for VLDL lipidation and binds to LDL receptors. Apo CII ($8.9\,kDa$) is a cofactor for lipoprotein lipase (LPL), while Apo CIII ($8.8\,kDa$) inhibits its effects. Apo E ($34.1\,kDa$) facilitates binding to receptors for Chylomicrons, VLDL, and HDL. Apo(a) ($187-662\,kDa$) is the protein component of Lipoprotein(a) [Lp(a)].

Lipoprotein Metabolism: Fuel and Overflow Pathways

Lipoprotein metabolism is divided into the fuel transport pathway and the overflow pathway. In the fuel transport pathway, Chylomicrons transport dietary triglycerides from the intestine to peripheral tissues post-prandially. Hepatic VLDL transports endogenous triglycerides during fasting. Lipoprotein lipase (LPL) hydrolyzes these triglycerides, releasing fatty acids for cellular use. Remnant particles, which are atherogenic, are eventually recaptured by the liver via the LRP or B/E receptors.

In the overflow pathway, LDL is generated from VLDL remnants. LDL is rich in cholesterol and has a long circulation time, making it highly atherogenic. LDL is taken up by the ApoB/E receptor in response to low intracellular cholesterol. Clinical indicators for these pathways include plasma determinations of total cholesterol, LDL-cholesterol, and triglycerides.

Reverse Cholesterol Transport involves the removal of excess cholesterol from peripheral cells to the liver. This starts with Pre-beta HDL and the ABCA1 transporter, moving free cholesterol to HDL. LCAT then esterifies the cholesterol, making HDL particles spherical (HDL3 and HDL2). The Cholesterol Ester Transfer Protein (CETP) facilitates the exchange of cholesterol esters for triglycerides between HDL and VLDL or LDL.

Pathophysiology of Atherosclerosis and Plaque Stability

Atherosclerosis begins with endothelial dysfunction, often triggered by risk factors like hypertension, diabetes, smoking, and dyslipidemias. Oxidized LDL (oxLDL) plays a central role by inducing the expression of adhesion molecules (VCAM-1, ICAM-1) and selectins, leading to monocyte recruitment and diapedesis into the intima. Monocytes differentiate into macrophages, which ingest oxLDL via scavenger receptors to become foam cells.

As the lesion progresses, fibrous tissue forms (fibrosis), creating a capsule over the lipid core. A "vulnerable plaque" is characterized by a thin capsule and a large lipid core, prone to rupture and thrombosis. A "stable plaque" has a thick capsule and a smaller lipid core. High-sensitivity C-reactive protein (hs-CRP) is a biomarker that induces adhesion molecules, activates complement, and promotes a pro-coagulant state by increasing PAI-1.

Definition and Classification of Dyslipidemias

Dyslipidemias are pathologies characterized by abnormal concentrations of blood lipids (Total-Col, HDL-Col, LDL-Col, or TG) that pose a health risk. They are a major modifiable risk factor for cardiovascular disease (CVD), particularly coronary artery disease.

They can be classified by etiopatogenia into Primary (Genetic) or Secondary. Secondary causes include lifestyle habits (alcohol, obesity, high-fat diet), pathologies (hypothyroidism, nephrotic syndrome, diabetes mellitus, chronic renal failure), and medications (androgens, beta-blockers, diuretics, estrogens, corticoids).

Phenotypic classification distinguishes four forms: Isolated Hypercholesterolemia (elevated LDL-C), Isolated Hypertriglyceridemia (elevated TG), Mixed Hyperlipidemia (elevated LDL-C and TG), and Isolated Low HDL-C. Total-Col over $240\,mg/dL$, LDL-C over $160\,mg/dL$, and TG over $400\,mg/dL$ are considered elevated.

Fredrickson Classification and Genetic Dyslipidemias

The Fredrickson-WHO classification system categorizes dyslipidemias into five types based on lipoprotein patterns. Type I involves increased Chylomicrons with massive TG elevation ($+++$). Type IIa involves increased LDL and cholesterol. Type IIb involves increased LDL and VLDL. Type III (Disbetalipoproteinemia) involves increased IDL remnants and is associated with Apo E2/E2 isoforms. Type IV involves increased VLDL, and Type V involves both VLDL and Chylomicrons. This classification is often used alongside visual inspections of plasma: milky or turbid samples indicate TG levels above $5.7\,mmol/L$.

Significant genetic dyslipidemias include Familial Hypercholesterolemia (FH), which occurs in $1:500$ individuals. It is an autosomal dominant defect in the LDL receptor, presenting with cholesterol levels between $300-400\,mg/dL$, corneal arc, and tendon xanthomas (especially the Achilles tendon). Familial Combined Hyperlipidemia (FCH) is the second most frequent ($1-2\%$ of the population), characterized by elevated Apo B and fluctuations in LDL or TG. Familial Hypertriglyceridemia involves TG over $250\,mg/dL$ and poses a risk of pancreatitis if TG exceeds $1000\,mg/dL$.

Laboratory Diagnosis and Analytical Considerations

The Friedewald formula is widely used to calculate LDL-cholesterol:

$Col\,LDL = Col\,total - Col-HDL - \frac{TG}{5}$

This formula assumes VLDL-cholesterol is equivalent to $\frac{TG}{5}$. It has critical limitations: it cannot be used if TG levels exceed $400\,mg/dL$ or if the patient has Chylomicronemia. Analytical variation is present in lipid testing, with Total Cholesterol having a total error of $\le 8.9\%$ and Triglycerides $\le 15\%$.

For accurate results, blood samples should be taken 12 hours after fasting (specifically for TG) and away from acute cardiovascular events (which can alter values for up to 3 months). Serum is preferred, and EDTA is used if transport is required to prevent lipid peroxidation and inhibit bacterial enzymes.

2026 Clinical Guidelines and Therapeutic Management

According to the 2026 ACC/AHA clinical guidelines, lipid management should prioritize early treatment, even in youth, especially for Familial Hypercholesterolemia. The PREVENT Risk Equations are used to estimate 10 and 30-year risk. Treatment goals are set based on risk: for secondary prevention (patients with CVD or diabetes), the LDL-C goal is $\le 100\,mg/dL$, and for very high risk, it is $< 55\,mg/dL$.

A significant 2026 update states that fasting is NOT required for most lipid profiles unless TG is $\ge 400\,mg/dL$ or there is a specific family history of premature ASCVD. Lipoprotein(a) [Lp(a)] should be measured at least once in a lifetime; levels $\ge 125\,nmol/L$ ($50\,mg/dL$) increase risk by $1.4\times$, while levels $\ge 250\,nmol/L$ ($100\,mg/dL$) increase it by $2\times$.

Pharmacological treatment involves Statins as the base therapy for reducing cardiovascular risk by inhibiting HMG-CoA reductase. Common side effects include myopathies, with rhabdomyolysis being the most severe. Fibrates, such as Gemfibrozil and Fenofibrate, are used to treat hypertriglyceridemia by inhibiting VLDL synthesis.

Questions & Discussion

Question: Is fasting always required for a lipid profile? Answer: No, the 2026 guidelines indicate that fasting is not required for most cases. It is only necessary if Triglycerides are above $400\,mg/dL$ or if there is a family history of dislipidemia or premature ASCVD.

Question: What are the markers for plaque stability? Answer: Plaque stability is determined by the thickness of the fibrous capsule. A thick capsule denotes a stable plaque, whereas a thin capsule with a large lipid core indicates a vulnerable plaque prone to rupture.

Question: When should treatment for hypertriglyceridemia be prioritized to prevent pancreatitis? Answer: Treatment is critical when Triglyceride levels reach or exceed $1000\,mg/dL$, as this significantly increases the risk of pancreatitis.